Medtronic (MDT Quick QuoteMDT - Free Report) reported $9.81 billion in revenue for the quarter ended April 2026, representing a year-over-year increase of 9.9%. EPS of $1.55 for the same period compares to $1.62 a year ago.

The reported revenue represents a surprise of +1.48% over the Zacks Consensus Estimate of $9.66 billion. With the consensus EPS estimate being $1.54, the EPS surprise was +0.58%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Medtronic performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Sales- U.S. Revenue: $4.87 billion versus the two-analyst average estimate of $4.95 billion. The reported number represents a year-over-year change of +7.1%.
• Net Sales- International: $4.94 billion versus $4.61 billion estimated by two analysts on average.
• Net Sales- World Wide Revenue: $9.81 billion versus $9.56 billion estimated by four analysts on average.
• Net Sales- World Wide Revenue- Other: $34 million versus $19.75 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +9.7% change.
• Net Sales- World Wide Revenue- Neuroscience: $2.75 billion versus the four-analyst average estimate of $2.78 billion. The reported number represents a year-over-year change of +5%.
• Net Sales- World Wide Revenue- Cardiovascular: $3.8 billion versus the four-analyst average estimate of $3.76 billion. The reported number represents a year-over-year change of +13.8%.
• Net Sales- World Wide Revenue- Medical Surgical: $2.39 billion versus $2.26 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +8% change.
• Net Sales- World Wide Revenue- Diabetes: $837 million versus $811.59 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +15% change.
• Net Sales- World Wide Revenue- Cardiovascular- Structural Heart & Aortic: $1 billion versus $1 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.1% change.
• Net Sales- World Wide Revenue- Medical Surgical- Surgical & Endoscopy: $1.82 billion versus the three-analyst average estimate of $1.74 billion. The reported number represents a year-over-year change of +6.5%.
• Net Sales- World Wide Revenue- Neuroscience- Neuromodulation: $542 million compared to the $552.86 million average estimate based on three analysts. The reported number represents a change of +4.2% year over year.
• Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies: $1.4 billion compared to the $1.43 billion average estimate based on three analysts. The reported number represents a change of +4.6% year over year.

View all Key Company Metrics for Medtronic here>>>

Shares of Medtronic have returned -5.2% over the past month versus the Zacks S&P 500 composite's +5.4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.